ConductScience.org, home

Paper498155

Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study.

Rossof AH and 7 others. Cancer Treat Rep, 1979. Cited by 82 papers, by iCite.

Cite this record

ConductScience Library. Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study. Papers, record 498155. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/498155

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study.
PubMed
Journal
Cancer Treat Rep
PubMed
Year
1979
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
82
iCite
Relative citation ratio, by iCite
2.37
iCite
Revised in PubMed
2013-11-21
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rossof AHA H
2Talley RWR W
3Stephens RR
4Thigpen TT
5Samson MKM K
6Groppe C JrC
7Eyre HJH J
8Fisher RR

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CisplatinMajor topic
Genital Neoplasms, FemaleMajor topic
Urogenital NeoplasmsMajor topic
Digestive System
Drug Evaluation
Female
Humans
Kidney
Male
Remission, Spontaneous

Source PubMed

Download CSV of topics

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 82 citations.

PMIDTitleJournalYearIn PapersSource
37996508Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.Sci Rep2023https://conductscience.org/library/papers/37996508PubMed
32668516Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options.Korean J Intern Med2020https://conductscience.org/library/papers/32668516PubMed
32160916Systematic analysis of ovarian cancer platinum-resistance mechanisms via text mining.J Ovarian Res2020https://conductscience.org/library/papers/32160916PubMed
30669514Platinum Resistance in Ovarian Cancer: Role of DNA Repair.Cancers (Basel)2019https://conductscience.org/library/papers/30669514PubMed
29255528Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer.J Rural Med2017https://conductscience.org/library/papers/29255528PubMed
28060758Exosomes as mediators of platinum resistance in ovarian cancer.Oncotarget2017https://conductscience.org/library/papers/28060758PubMed
26463832Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.Cancer Discov2015https://conductscience.org/library/papers/26463832PubMed
26308952Conditional Survival in de novo Metastatic Urothelial Carcinoma.PLoS One2015https://conductscience.org/library/papers/26308952PubMed
25429526Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17).Br J Cancer2015https://conductscience.org/library/papers/25429526PubMed
24722472CKD-EPI and cockcroft-gault equations identify similar candidates for neoadjuvant chemotherapy in muscle-invasive bladder cancer.PLoS One2014https://conductscience.org/library/papers/24722472PubMed
24624361Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System.Front Oncol2014https://conductscience.org/library/papers/24624361PubMed
21789133Practical considerations in ovarian cancer chemotherapy.Ther Adv Med Oncol2010https://conductscience.org/library/papers/21789133PubMed
17712400Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?Cancer Ther2007https://conductscience.org/library/papers/17712400PubMed
16683074A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.Invest New Drugs2006https://conductscience.org/library/papers/16683074PubMed
15528984Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).Invest New Drugs2005https://conductscience.org/library/papers/15528984PubMed
7149776Chemotherapy for advanced recurrent carcinoma of the cervix. A report on the treatment of 22 patients.Arch Gynecol1982https://conductscience.org/library/papers/7149776PubMed
6371015Developing new drugs for ovarian cancer: a challenging task in a changing reality.J Cancer Res Clin Oncol1984https://conductscience.org/library/papers/6371015PubMed
6357518Chemotherapy of advanced transitional cell carcinoma of the uroepithelium.Cancer Chemother Pharmacol1983https://conductscience.org/library/papers/6357518PubMed
3909096Cisplatin: a review of clinical applications and renal toxicity.Pharm Weekbl Sci1985https://conductscience.org/library/papers/3909096PubMed
3192385Phase I--preliminary phase II trial of iproplatin, a cisplatin analogue.Invest New Drugs1988https://conductscience.org/library/papers/3192385PubMed

See all 21 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/498155

GET https://conductscience.org/api/papers/v1/498155/cited_by?page=2